The effectiveness opens the door for selling stockholders to liquidate their positions. The large block relative to daily volume could pressure the stock. Watch for Form 4 filings and volume spikes indicating insider selling. The prior S-1 from May 2026 also remains effective, adding to potential overhang.
Price Chart
Executive Summary
The SEC declared effective First Tracks Biotherapeutics' S-1 registration (File No. 333-299632) on October 29, 2026, enabling the resale of up to 6,106,870 shares by selling stockholders from an October 2026 private placement. The company receives no proceeds, but the registered shares represent approximately 14.5% of outstanding stock, creating a potential overhang.
Key Facts
- EFFECT notice for S-1 registration (File No. 333-299632) became effective on October 29, 2026.
- Registration covers resale of up to 6,106,870 shares of common stock by selling stockholders.
- Company receives no proceeds from this offering.
- Shares were issued in a private placement that closed October 19, 2026, raising ~$200 million at $32.75 per share.
- Registered shares represent ~14.5% of outstanding shares based on market cap of $1.9B and $32.75 price.
- A prior S-1 (May 2026) registered 10,497,054 shares from an earlier private placement, also with no proceeds to the company.
Financial Impact
Up to 6,106,870 shares (~14.5% of outstanding) eligible for resale; no proceeds to company.
Risk Factors
- Potential selling pressure from stockholders holding ~14.5% of shares now eligible for resale.
- Combined overhang from this and the May 2026 S-1 (10.5M shares) could amplify downward pressure.
- No company proceeds means no offsetting capital benefit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003380 |
| Document: 9999999995-26-003380-index.html | 9999999995-26-003380 |
| Document: 9999999995-26-003380.txt | 9999999995-26-003380 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | EFFECT | $45.23 | awaiting T+1 | awaiting T+1 | $45.08 (+0.33%) |
Oct 27, 2026 4d ago | SC 13G/A | $45.72 $45.23 | ▼ −1.08% | ▼ −0.70% | $45.08 (−1.40%) |
Oct 26, 2026 6d ago | S-1 | $43.48 $45.38 | ▲ +4.37% | ▲ +3.81% | $45.08 (+3.68%) |
Oct 20, 2026 11d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $45.08 (+5.40%) |
Oct 15, 2026 16d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $45.08 (−30.82%) |
Oct 15, 2026 17d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $45.08 (−25.08%) |
Oct 13, 2026 19d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $45.08 (+42.30%) |
Aug 12, 2026 11w ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Aug 12, 2026 11w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $45.08 (+2.38%) |
Aug 7, 2026 12w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $45.08 (−5.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers